IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

Novo Nordisk launched access to its popular weight loss GLP-1 drug, Wegovy, through multiple telehealth platforms, including Hims & Hers.

The strategy comes as rival Eli Lilly & Co. is working with telehealth firms to distribute lower-cost vials of its own ...

Novo Nordisk NVO is expected to beat estimates when it reports its first-quarter 2025 results before the opening bell on May ...

She suggested I start taking the GLP-1 Zepbound through weekly injections, along with incorporating a healthy diet and ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate ...

President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

But recent weak U.S. prescription data is leading some investors and analysts to question whether that stellar run, which ...

After reporting robust results, Resmed reckons it won't be subject to US tariffs while the growth of anti-obesity drugs will be a tailwind.

Glucagon-like peptide 1 receptor agonists, which are found in Ozempic-like drugs, can could cause devastating symptoms in ...